Patient characteristics for signaling analysis
| . | PV . | ET . | MF* . | Control . |
|---|---|---|---|---|
| n | 10 | 13 | 8 | 6 |
| Demographics | ||||
| Female/male (%) | 8/2 (80%/20%) | 6/7 (46%/54%) | 3/5 (38%/62%) | 2/4 (33%/66%) |
| Median age, yr | 75 | 72 | 66 | 57 |
| Clinical details | ||||
| Diagnostic sample (D) | 10 of 10 (100%) | 7 of 13 (54%) | 1 of 8 (12%) | |
| Treated (T)† | 6 of 13(46%) | 7 of 8 (88%) | ||
| Laboratory features‡ | ||||
| Sample type | All BM | BM 11 of 13; PB 2 of 13 | BM 2 of 8; PB 6 of 8 | |
| V617F mutation, n (%) | 8 of 10 (80%) | 4 of 13 (31%) | 4 of 8 (50%) | |
| Exon 12 mutation, n (%) | 2 of 10 (20%) | |||
| cMPL mutation, n (%)§ | 3 of 13 (23%) | 1 of 8 (12%) | ||
| Median hemoglobin, g/L‡ | 152 | (D) 143; (T) 113 | (D) 106; (T) 95 | 144 |
| Median white cells, ×109/L‡ | 10 | (D) 8.6; (T) 5.8 | (D) 9.1; (T) 15.1 | 7.4 |
| Median platelet count, ×109/L‡ | 412 | (D) 965; (T) 403 | (D) 1149; (T) 267 | 247 |
| . | PV . | ET . | MF* . | Control . |
|---|---|---|---|---|
| n | 10 | 13 | 8 | 6 |
| Demographics | ||||
| Female/male (%) | 8/2 (80%/20%) | 6/7 (46%/54%) | 3/5 (38%/62%) | 2/4 (33%/66%) |
| Median age, yr | 75 | 72 | 66 | 57 |
| Clinical details | ||||
| Diagnostic sample (D) | 10 of 10 (100%) | 7 of 13 (54%) | 1 of 8 (12%) | |
| Treated (T)† | 6 of 13(46%) | 7 of 8 (88%) | ||
| Laboratory features‡ | ||||
| Sample type | All BM | BM 11 of 13; PB 2 of 13 | BM 2 of 8; PB 6 of 8 | |
| V617F mutation, n (%) | 8 of 10 (80%) | 4 of 13 (31%) | 4 of 8 (50%) | |
| Exon 12 mutation, n (%) | 2 of 10 (20%) | |||
| cMPL mutation, n (%)§ | 3 of 13 (23%) | 1 of 8 (12%) | ||
| Median hemoglobin, g/L‡ | 152 | (D) 143; (T) 113 | (D) 106; (T) 95 | 144 |
| Median white cells, ×109/L‡ | 10 | (D) 8.6; (T) 5.8 | (D) 9.1; (T) 15.1 | 7.4 |
| Median platelet count, ×109/L‡ | 412 | (D) 965; (T) 403 | (D) 1149; (T) 267 | 247 |
MPN patients were mainly analyzed at diagnosis (18 of 31, 58%). In all patients with PV, 11 of 13 with ET, and 2 of 8 with MF (23 of 31, 74%), the material analyzed was BM; however, in 6 of 8 patients with MF and 2 of 13 patients with ET, due to an inability to obtain BM, peripheral blood (PB) was used. The 6 control samples were obtained from lymphoma staging marrows with no marrow involvement.
Includes primary MF (4 of 8) and MF secondary to preceding PV (4 of 8).
Patients have received cytotoxic chemotherapy in the previous 6 months.
At the time of sampling.
ET, 1 MPL exon 10 W515R mutation and 2 MPL exon 10 W515L mutations; MF, exon 10 W515L mutation.